From: HIV-tat alters Connexin43 expression and trafficking in human astrocytes: role in NeuroAIDS
Cx30 expression in astrocytes (percentage of control, n = 3) | ||||
---|---|---|---|---|
Treatment (virus) | 7 days | 14 days | 21 days | 28 days |
HIVADA (20 ng/ml) | −12.3 ± 9.9* | −22.5 ± 8.9* | −32 ± 9.88* | −38.9 ± 7.9* |
HIVJR-CSF (20 ng/ml) | −28.7 ± 6.8* | −32.7 ± 11* | −49.8 ± 14.6* | −65.5 ± 21.2* |
Treatment (recombinant proteins) | 6Â h | 12Â h | 24Â h | 48Â h |
Vif (1, 100, and 300 ng/ml) | −3.8 ± 1.06* | −5.99 ± 2.3* | −8.88 ± 4.5 * | −8.98 ± 5.6* |
Gag (p55, p24, or p7: 1, 100, and 300Â ng/ml) | No change | No change | No change | No change |
Rev (1, 100, and 250Â ng/ml) | No change | No change | No change | No change |
Nef (1, 100, and 250 ng/ml) | −5.3 ± 3.2* | −8.6 ± 3.43* | −12.7 ± 6.6* | −14.9 ± 7.45* |
Gp120 (1, 50, and 100 nM) | −3.44 ± 2.1* | −5.6 ± 5.4* | −8.88 ± 4.3* | −9.15 ± 3.3* |
HIV-tat1–72 (1, 100, and 300 ng/ml) | −9.02 ± 3.3* | −10.5 ± 5.4* | −17.5 ± 3.9* | −28.1 ± 11.8* |
IL-1β (10 ng/ml) | −21.7 ± 8.9* | −36.54 ± 9* | −51.3 ± 9.3* | −52.3 ± 21.5* |